<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is the second most frequent non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> accounting for about 10-20% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in western countries </plain></SENT>
<SENT sid="1" pm="."><plain>The median age at diagnosis is 60 years old </plain></SENT>
<SENT sid="2" pm="."><plain>The clinical presentation is usually characterized by asymptomatic peripheral <z:mp ids='MP_0000702'>adenopathy</z:mp> in cervical, axillary, inguinal and femoral regions </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment options for patients with na√Øve or recurrent follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are still controversial, ranging from a "watch and wait" policy to hematopoietic stem cell transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>More recently, the availability of rituximab has substantially changed follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> therapeutic approaches to such an extent that R-Chemo is now the standard induction first-line treatment </plain></SENT>
<SENT sid="5" pm="."><plain>This review provides a general overview of the state of the art in the management of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and also, a brief description regarding the current prognostic tools available for treatment decisions </plain></SENT>
</text></document>